These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17997799)

  • 21. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
    Okunade G; Green AR; Ying M; Agrawal A; Paish EC; Aleskandrany M; Winterbottom L; Hassell K; Morgan DA; Ellis IO; Cheung KL
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):76-82. PubMed ID: 19515574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
    Schwartzberg LS; Cobb P; Senecal F; Henry D; Kulig K; Walker MS; Houts AC; Stepanski EJ
    Breast; 2009 Apr; 18(2):78-83. PubMed ID: 19342237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M; Yamashiro H; Tsuji W
    Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2D6 genotyping and the pharmacogenetics of tamoxifen.
    Flockhart D
    Clin Adv Hematol Oncol; 2008 Jul; 6(7):493-4. PubMed ID: 18654115
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
    Peppercorn J; A Carey L
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
    Kahán Z
    Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
    [No Abstract]   [Full Text] [Related]  

  • 30. Tamoxifen-induced radiation recall dermatitis.
    Kundranda MN; Daw HA
    Am J Clin Oncol; 2006 Dec; 29(6):637-8. PubMed ID: 17149005
    [No Abstract]   [Full Text] [Related]  

  • 31. Do some antidepressants decrease effect of tamoxifen?
    J Support Oncol; 2009; 7(4):147-8. PubMed ID: 19731582
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
    Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
    Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
    Snoj N; Paridaens R; Cufer T
    Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
    Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
    Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
    Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
    Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-grade endometrial stromal sarcoma following tamoxifen treatment.
    Engin H
    Gynecol Oncol; 2008 Jan; 108(1):253-4. PubMed ID: 17928038
    [No Abstract]   [Full Text] [Related]  

  • 38. [Response of F. Leung, J.-J. Terzibachian and D. Riethmuller to the article of M. Saim et al. Malignant mixed Müllerian tumor of the uterus following tamoxifen for breast cancer: case report. Gynecol Obstet Fertil 2008;36:166-8].
    Leung F; Terzibachian JJ; Riethmuller D
    Gynecol Obstet Fertil; 2008; 36(7-8):828-9. PubMed ID: 18656415
    [No Abstract]   [Full Text] [Related]  

  • 39. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study.
    Martelli G; Miceli R; Costa A; Coradini D; Zurrida S; Piromalli D; Vetrella G; Greco M
    Cancer; 2008 Feb; 112(3):481-8. PubMed ID: 18098268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association.
    Hernandez RK; Sørensen HT; Jacobsen J; Pedersen L; Lash TL
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2509-11. PubMed ID: 18768523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.